BioCentury | Feb 25, 2021
Deals

Feb. 24 Quick Takes: ICON buying PRA in $12B CRO deal; plus venture rounds for Yisheng, Xilio, Truvian, Lyvgen, AmacaThera, and more

...platform. Staff Writer Hongjiang Li contributed to this report. Jeff Cranmer ICON plc PRA Health Sciences Yisheng Biopharma Co. Ltd. Xilio Therapeutics Inc. Truvian...
BioCentury | Aug 29, 2020
Product Development

Next-wave Th1 cytokine cancer therapies aim for more precise targeting

...an IL-2 variant and an anti-PD-1 mAb. Xilio Therapeutics Inc....
...Inc. Ascendis Pharma A/S Iovance Biotherapeutics Inc. Medicenna Therapeutics Corp. Philogen S.p.A. Xilio Therapeutics Inc. Inovio...
BioCentury | Jul 16, 2020
Emerging Company Profile

Adimab spinout aims for neutralizing mAbs more effective than coronavirus vaccines

...round of financing in the fall. Gerngross said Chair Rene Russo, CEO of cancer play Xilio Therapeutics Inc....
BioCentury | Jun 20, 2020
Management Tracks

Nurix bolsters leadership; plus Lynch named Xilio chairman, Edgewise, BioXCel, Catabasis, Catalyst and more

...team lead at Allogene Therapeutics Inc. (NASDAQ:ALLO) (see “Nurix raises $120M” ). Tumor-activated immunotherapy play Xilio Therapeutics Inc....
...CMO. She was VP of clinical development at Merus N.V. (NASDAQ:MRUS). Robin Sawka, BioCentury Staff Nurix Therapeutics Inc. Xilio Therapeutics Inc. Edgewise...
BioCentury | Apr 30, 2020
Management Tracks

Desmond-Hellmann joins GV as adviser; plus Radius, Anika, AMAG, AiCure and more

...developing calcineurin inhibitor voclosporin to treat lupus nephritis, focal segmental glomerulosclerosis and dry eye symptoms. Xilio Therapeutics Inc....
BioCentury | Mar 2, 2020
Finance

Xilio to deploy $100M B round toward POC for tumor-activated immunotherapies

...Venture and additional undisclosed investors. Formerly Akrevia Therapeutics LLC, the company changed its name to Xilio Therapeutics Inc....
...IL-15 - Interleukin-15 Sandi Wong, Assistant Editor Akrevia Therapeutics LLC Interleukin-2 (IL-2) Cytotoxic T-lymphocyte associated protein 4 (CTLA-4) (CTLA4) (CD152) Xilio Therapeutics Inc. XTX201 XTX101...
Items per page:
1 - 6 of 6
BioCentury | Feb 25, 2021
Deals

Feb. 24 Quick Takes: ICON buying PRA in $12B CRO deal; plus venture rounds for Yisheng, Xilio, Truvian, Lyvgen, AmacaThera, and more

...platform. Staff Writer Hongjiang Li contributed to this report. Jeff Cranmer ICON plc PRA Health Sciences Yisheng Biopharma Co. Ltd. Xilio Therapeutics Inc. Truvian...
BioCentury | Aug 29, 2020
Product Development

Next-wave Th1 cytokine cancer therapies aim for more precise targeting

...an IL-2 variant and an anti-PD-1 mAb. Xilio Therapeutics Inc....
...Inc. Ascendis Pharma A/S Iovance Biotherapeutics Inc. Medicenna Therapeutics Corp. Philogen S.p.A. Xilio Therapeutics Inc. Inovio...
BioCentury | Jul 16, 2020
Emerging Company Profile

Adimab spinout aims for neutralizing mAbs more effective than coronavirus vaccines

...round of financing in the fall. Gerngross said Chair Rene Russo, CEO of cancer play Xilio Therapeutics Inc....
BioCentury | Jun 20, 2020
Management Tracks

Nurix bolsters leadership; plus Lynch named Xilio chairman, Edgewise, BioXCel, Catabasis, Catalyst and more

...team lead at Allogene Therapeutics Inc. (NASDAQ:ALLO) (see “Nurix raises $120M” ). Tumor-activated immunotherapy play Xilio Therapeutics Inc....
...CMO. She was VP of clinical development at Merus N.V. (NASDAQ:MRUS). Robin Sawka, BioCentury Staff Nurix Therapeutics Inc. Xilio Therapeutics Inc. Edgewise...
BioCentury | Apr 30, 2020
Management Tracks

Desmond-Hellmann joins GV as adviser; plus Radius, Anika, AMAG, AiCure and more

...developing calcineurin inhibitor voclosporin to treat lupus nephritis, focal segmental glomerulosclerosis and dry eye symptoms. Xilio Therapeutics Inc....
BioCentury | Mar 2, 2020
Finance

Xilio to deploy $100M B round toward POC for tumor-activated immunotherapies

...Venture and additional undisclosed investors. Formerly Akrevia Therapeutics LLC, the company changed its name to Xilio Therapeutics Inc....
...IL-15 - Interleukin-15 Sandi Wong, Assistant Editor Akrevia Therapeutics LLC Interleukin-2 (IL-2) Cytotoxic T-lymphocyte associated protein 4 (CTLA-4) (CTLA4) (CD152) Xilio Therapeutics Inc. XTX201 XTX101...
Items per page:
1 - 6 of 6